Drugs / TQB3006
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06344351 | Apr 2024 → May 2025 | cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB3006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06344351 ↗ |
| Action | Inhibit | “TQB3006 is an inhibitor protein.” NCT06344351 ↗ |
| Modality | Protein / enzyme biologic | “TQB3006 is an inhibitor protein.” NCT06344351 ↗ |
| Route | Oral | “Take TQB3006 orally on an empty stomach once or twice a day” NCT06344351 ↗ |